Bioworld Insider

Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

About episode

Iteos Therapeutics inc. has come a long way in the past year. The company went public in July 2020 and this week inked a deal with Glaxosmithkline plc (GSK) that could top $2 billion. Iteos brings GSK a human monoclonal antibody targeting TIGIT, the third of the known CD226 checkpoints that the company wanted for its cancer therapy program. The two companies plan to split U.S. profits, something that Iteos insisted upon as part of the deal. Iteos is receiving $625 million as an up-front payment and up to $1.45 billion in potential milestone payments.

In this episode, BioWorld Staff Writer Lee Landenberger caught up with Michel Detheux, president and CEO of Iteos, who said the company was in a strong financial position and didn’t need a deal this size, but the cash infusion will significantly boost its PD-1 development programs.

About BioWorld Insider

The BioWorld Insider Podcasts provides timely and focused one-on-one interviews with the same key sources typically interviewed for articles such as company founders, executives, top researchers and regulators. Topics are prioritized based on the same criteria we use when selecting news to feature in BioWorld, which for more than 30 years reports the breaking news — and provides key perspective — on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.